■ The Glaukos Idose TR sustained-release travoprost implant continued to provide sustained substantial IOP reductions by 36 months, according to phase 2b data from 154 subjects. The Idose TR contains a novel formulation of travoprost that releases at therapeutic levels for at least 1 year, according to the manufacturer. The implant, a potential alternative to daily drops, is administered during a microinvasive procedure. Once the drug supply is exhausted, the Idose is removed and replaced with a new one.

The multicenter, randomized, double-blind phase 2b trial was designed to evaluate a single administration of 1 of 2 Idose TR models with different travoprost release rates compared to topical timolol ophthalmic solution, 0.5% twice daily. According to a company news release, in the fast-release and slow-release Idose TR arms, 70% and 68% of subjects respectively were well controlled with the same or fewer IOP-lowering topical medications at 36 months vs screening, vs 46% of subjects in the timolol control arm.